Ultragenyx Pharmaceutical | RARE - Selling And Administration Expenses

Stock Price
24.85
Daily Change
0.78 3.24%
Monthly
7.53%
Yearly
-42.77%
Q1 Forecast
23.33

Ultragenyx Pharmaceutical reported $86.62M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Insmed USD 186.38M 109.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Kyowa Hakko Kirin JPY 38.72B 2.06B Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
Moderna USD 268M 38M Sep/2025
Neurocrine Biosciences USD 291.6M 5.3M Sep/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025
Vertex Pharmaceuticals USD 445.1M 20.5M Sep/2025